JP2008521795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521795A5 JP2008521795A5 JP2007542513A JP2007542513A JP2008521795A5 JP 2008521795 A5 JP2008521795 A5 JP 2008521795A5 JP 2007542513 A JP2007542513 A JP 2007542513A JP 2007542513 A JP2007542513 A JP 2007542513A JP 2008521795 A5 JP2008521795 A5 JP 2008521795A5
- Authority
- JP
- Japan
- Prior art keywords
- leptin
- antagonist
- seq
- leptin antagonist
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016267 Leptin Human genes 0.000 claims 30
- 108010092277 Leptin Proteins 0.000 claims 30
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical group O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 26
- 229940039781 leptin Drugs 0.000 claims 26
- 239000005557 antagonist Substances 0.000 claims 22
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 235000004279 alanine Nutrition 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 102000049953 human LEP Human genes 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 101001004853 Ovis aries Leptin Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000004475 Arginine Chemical group 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Chemical group 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/996,607 | 2004-11-26 | ||
| US10/996,607 US7307142B2 (en) | 2004-11-26 | 2004-11-26 | Leptin antagonists |
| PCT/IL2005/001250 WO2006056987A2 (en) | 2004-11-26 | 2005-11-24 | Leptin antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521795A JP2008521795A (ja) | 2008-06-26 |
| JP2008521795A5 true JP2008521795A5 (enExample) | 2009-02-05 |
| JP5113526B2 JP5113526B2 (ja) | 2013-01-09 |
Family
ID=36204374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007542513A Expired - Fee Related JP5113526B2 (ja) | 2004-11-26 | 2005-11-24 | レプチン拮抗薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7307142B2 (enExample) |
| EP (1) | EP1814986B1 (enExample) |
| JP (1) | JP5113526B2 (enExample) |
| CN (1) | CN101189335B (enExample) |
| AT (1) | ATE498683T1 (enExample) |
| DE (1) | DE602005026432D1 (enExample) |
| ES (1) | ES2363011T3 (enExample) |
| WO (1) | WO2006056987A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| WO2009143380A2 (en) * | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
| WO2010054017A1 (en) * | 2008-11-04 | 2010-05-14 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
| WO2010117785A1 (en) * | 2009-03-31 | 2010-10-14 | Temple University - Of The Commonwealth System Of Higher Education | Leptin antagonist and methods of use |
| MX2012012229A (es) * | 2010-04-22 | 2013-03-05 | Yissum Res Dev Co | Leptinas de alta afinidad y antagonistas de leptina. |
| WO2014024189A1 (en) * | 2012-08-06 | 2014-02-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Pegylated high affinity leptins with increased biological activity |
| IT1423968B1 (enExample) * | 2014-04-28 | 2016-08-26 | ||
| CA2977607A1 (en) * | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
| US10926006B2 (en) | 2015-02-26 | 2021-02-23 | Remodeless Cv Ltd | Drug eluting stent |
| US11123461B2 (en) | 2015-02-26 | 2021-09-21 | Remodeless Cv Ltd | Treatment of ischemia and reperfusion using leptin antagonist |
| CN104829707B (zh) | 2015-05-06 | 2017-12-19 | 广东省生物资源应用研究所 | 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用 |
| CN104829708B (zh) * | 2015-05-06 | 2017-11-28 | 广东省生物资源应用研究所 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| US10550192B2 (en) * | 2016-11-08 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| EP3898672A1 (en) | 2018-12-18 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
| WO2024050285A2 (en) * | 2022-08-31 | 2024-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Leptin analogs for treating obesity and weight management |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| AU1406497A (en) * | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
| US20020160935A1 (en) | 2000-03-24 | 2002-10-31 | Smithkline Beecham Plc | Use of leptin antagonists for the treatment of diabetes |
| HUP9904023A3 (en) | 1996-09-20 | 2002-01-28 | Hoechst Ag | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| CA2437265A1 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified leptin with reduced immunogenicity |
-
2004
- 2004-11-26 US US10/996,607 patent/US7307142B2/en not_active Expired - Fee Related
-
2005
- 2005-11-24 DE DE602005026432T patent/DE602005026432D1/de not_active Expired - Lifetime
- 2005-11-24 EP EP05809259A patent/EP1814986B1/en not_active Expired - Lifetime
- 2005-11-24 CN CN2005800471206A patent/CN101189335B/zh not_active Expired - Fee Related
- 2005-11-24 ES ES05809259T patent/ES2363011T3/es not_active Expired - Lifetime
- 2005-11-24 AT AT05809259T patent/ATE498683T1/de not_active IP Right Cessation
- 2005-11-24 WO PCT/IL2005/001250 patent/WO2006056987A2/en not_active Ceased
- 2005-11-24 JP JP2007542513A patent/JP5113526B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521795A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| RU2016103067A (ru) | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей | |
| JP2011511753A5 (enExample) | ||
| JP2009524429A5 (enExample) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2013515055A5 (enExample) | ||
| JP2013515057A5 (enExample) | ||
| NZ606427A (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2010529860A5 (enExample) | ||
| JP2008536483A5 (enExample) | ||
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| ATE350049T1 (de) | Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1 | |
| JP2003533186A5 (enExample) | ||
| JP2009533317A5 (enExample) | ||
| JP2006514820A5 (enExample) | ||
| WO2007018619A3 (en) | Chimeric therapeutic agents | |
| DE602004027362D1 (de) | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 | |
| JP2012518669A5 (enExample) | ||
| JP2006514822A5 (enExample) | ||
| EP1982992A4 (en) | HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR | |
| JP2008510468A5 (enExample) | ||
| JP2019038772A5 (enExample) | ||
| DE60234103D1 (de) | Kontrolle des wachstums und der reparatur von gastrointestinalgewebe durch gastrokine | |
| JP2007536910A5 (enExample) |